HighGravityData
Companies / Hologic / Filing

Hologic — May 1, 2025 release

Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001140361-25-016906
Open on SEC.gov ↗
Showing in the filing
Diluted shares outstanding
“approximately 228 million”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 22
Non-GAAP tax rate for FY2025
“approximately 19.25%”
Non-GAAP tax rate assumption for FY2025
“approximately 19.25%”
Diluted shares outstanding for FY2025
“approximately 228 million”
Diluted shares outstanding assumption for FY2025
“approximately 228 million”
Revenue for FY2025
“$4,050 - $4,100”
Revenue Reported % Increase (Decrease) for FY2025
“0.5% to 1.7%”
Revenue Constant Currency % Increase (Decrea… for FY2025
“0.8% to 2.1%”
Revenue Organic % Increase (Decrease) for FY2025
“(0.7%) to 0.5%”
Revenue Organic excluding COVID-19 % Increas… for FY2025
“0.3% to 1.6%”
GAAP EPS for FY2025
“$2.47 - $2.57”
GAAP EPS Reported % Increase (Decrease) for FY2025
“(25.6%) to (22.6%)”
Non-GAAP EPS for FY2025
“$4.15 - $4.25”
Non-GAAP EPS Reported % Increase (Decrease) for FY2025
“1.7% to 4.2%”
Revenue for Q3 FY2025
“$1,000 - $1,010”
Revenue Reported % Increase (Decrease) for Q3 FY2025
“(1.1%) to (0.1%)”
Revenue Constant Currency % Increase (Decrea… for Q3 FY2025
“(1.0%) to (0.0%)”
Revenue Organic % Increase (Decrease) for Q3 FY2025
“(3.5%) to (2.5%)”
Revenue Organic excluding COVID-19 % Increas… for Q3 FY2025
“(2.9%) to (1.8%)”
GAAP EPS for Q3 FY2025
“$0.85 - $0.88”
GAAP EPS Reported % Increase (Decrease) for Q3 FY2025
“3.7% to 7.3%”
Non-GAAP EPS for Q3 FY2025
“$1.04 - $1.07”
Non-GAAP EPS Reported % Increase (Decrease) for Q3 FY2025
“(1.9%) to 0.9%”
Exhibit 99.1 · the passage around this item
… earlier in the release
Hologic’s financial guidance for the third quarter and full year 2025 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 19.25%, and diluted shares outstanding of approximately 228 million for the full year.  Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2025 as in fiscal 2024.  Organic revenue guidance for fiscal 2025 is in constant currency and excludes the divested blood screening and SSI ultrasound imaging businesses.  Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition.  In fiscal 2025, revenue from the acquired Endomagnetics business becomes organic in August.  Revenue from the acquired Gynesonics business will be excluded from organic revenue for all of fiscal 2025.  Organic revenue excluding COVID-19 is in constant currency and is organic revenue excluding COVID-19 assay revenue, COVID-19 related revenue, and discontinued product sales in diagnostics.     Current Guidance   Previous Guidance       Guidance $   Reported % Increase (Decrease) Constant Currency % Increase (Decrease) Organic % Increase (Decrease) Organic excluding COVID-19 % Increase (Decrease)   Guidance $   Fiscal 2025                     Revenu
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.